Expression of MicroRNAs miR-145, miR-181c, miR-199a and miR-1183 in the Blood and Hippocampus of Patients with Mesial Temporal Lobe Epilepsy

Antônio, Luana Grupioni Lourenço; Freitas‐Lima, Priscila; Pereira-da-Silva, Gabriela; Assirati, João Alberto; Matias, Caio; Cirino, Mucio Luiz Assis; Tirapelli, Luís Fernando; Velasco, Tonicarlo Rodrigues; Sakamoto, Américo Ceiki; Carlotti, Carlos Gilberto

doi:10.1007/s12031-019-01386-w

Cited by 25 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far, new biomarkers for the diagnosis of epilepsy are still being evaluated. The expression changes of various miRNAs identified by expression profiling of circulating miRNA have been confirmed in epilepsy patients (Antônio et al, 2019;Brennan et al, 2020). There is evidence that epilepsy is associated with the expression changes observed in the circulating miRNAs.…”

Section: Mirnas As Biomarkers Of Epilepsymentioning

confidence: 82%

“…They found that miR-134 was significantly downregulated in the plasma of MTLE patients, suggesting that decreased hsa-miR-134 expression could be a potential non-invasive biomarker to support the diagnosis of patients with MTLE. Other potential circulating biomarkers are miR-145, miR-181c, miR-199a, and miR-1183, which were overexpressed in the blood of patients with MTLE with hippocampal sclerosis (MTLE-HS) (Antônio et al, 2019). Serum miR-328-3p is also an important peripheral biomarker for the diagnosis of MTLE-HS with high area under the curve (AUC) values when comparing controls to Engel I (90.3%).…”

Section: Mirnas As Biomarkers Of Epilepsymentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA Dysregulation in Epilepsy: From Pathogenetic Involvement to Diagnostic Biomarker and Therapeutic Agent Development

Wang

Zhao

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Epilepsy is the result of a group of transient abnormalities in brain function caused by an abnormal, highly synchronized discharge of brain neurons. MicroRNA (miRNA) is a class of endogenous non-coding single-stranded RNA molecules that participate in a series of important biological processes. Recent studies demonstrated that miRNAs are involved in a variety of central nervous system diseases, including epilepsy. Although the exact mechanism underlying the role of miRNAs in epilepsy pathogenesis is still unclear, these miRNAs may be involved in the inflammatory response in the nervous system, neuronal necrosis and apoptosis, dendritic growth, synaptic remodeling, glial cell proliferation, epileptic circuit formation, impairment of neurotransmitter and receptor function, and other processes. Here, we discuss miRNA metabolism and the roles of miRNA in epilepsy pathogenesis and evaluate miRNA as a potential new biomarker for the diagnosis of epilepsy, which enhances our understanding of disease processes.

show abstract

Section: Mirnas As Biomarkers Of Epilepsymentioning

confidence: 82%

Section: Mirnas As Biomarkers Of Epilepsymentioning

confidence: 99%

MicroRNA Dysregulation in Epilepsy: From Pathogenetic Involvement to Diagnostic Biomarker and Therapeutic Agent Development

Wang

Zhao

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…We performed a manual literature search in PubMed and the Human MicroRNA Disease Database (HMDD; v3.2) with the combined keywords “FCD, seizures, epilepsy or status epilepticus” and the four upregulated miRNAs (miR-194-2, miR-15a, miR-132, and miR-145), to confirm the relationship between the miRNAs and FCD or different types of seizures and epilepsy [ 52 ] ( Table 2 ). According to the reported literature in PubMed, these miRNAs related to FCD and different forms of seizures and epilepsy [ 30 , 31 , 53 , 54 , 55 , 56 , 57 ] were identified, including the reported evidence of diagnostic and prognostic biomarkers and therapeutic targets ( Table 2 ). Each single miRNA can influence multiple genes.…”

Section: Resultsmentioning

confidence: 99%

“…miR194-2 and miR-15a are notably downregulated in epilepsy patients, so they may be used as novel biomarkers for the improved diagnosis and prognostic prediction in epilepsy [ 53 , 54 ]. In a human study, miR-145 was noted to be hypo-expressed in the surgical hippocampal tissues, but hyperexpressed in the blood of patients with mesial temporal lobe sclerosis [ 57 ]. However, another study [ 30 ] showed that miR-145 was significantly downregulated in the peripheral blood of patients with mesial temporal lobe epilepsy.…”

Section: Discussionmentioning

confidence: 99%

Circulating MicroRNAs from Serum Exosomes May Serve as a Putative Biomarker in the Diagnosis and Treatment of Patients with Focal Cortical Dysplasia

Chen

Pan

Huang

et al. 2020

Cells

View full text Add to dashboard Cite

Focal cortical dysplasia (FCD) is a congenital malformation of cortical development where the cortical neurons located in the brain area fail to migrate in the proper formation. Epilepsy, particularly medically refractory epilepsy, is the most common clinical presentation for all types of FCD. This study aimed to explore the expression change of circulating miRNAs in patients with FCD from serum exosomes. A total of nine patients with FCD and four healthy volunteers were enrolled in this study. The serum exosomes were isolated from the peripheral blood of the subjects. Transmission electron microscopy (TEM) was used to identify the exosomes. Both exosomal markers and neuronal markers were detected by Western blotting analysis to prove that we could obtain central nervous system-derived exosomes from the circulation. The expression profiles of circulating exosomal miRNAs were assessed using next-generation sequencing analysis (NGS). We obtained a total of 107 miRNAs with dominant fold change (>2-fold) from both the annotated 5p-arm and 3p-arm of 2780 mature miRNAs. Based on the integrated platform of HMDD v3.2, miRway DB and DIANA-miRPath v3.0 online tools, and confirmed by MiRBase analysis, four potentially predicted miRNAs from serum exosomes in patients with FCD were identified, including miR194-2-5p, miR15a-5p, miR-132-3p, and miR-145-5p. All four miRNAs presented upregulated expression in patients with FCD compared with controls. Through Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and pathway category of four target miRNAs, we found eight possible signaling pathways that may be related to FCD. Among them, we suggest that the mTOR signaling pathway, PI3K-Akt signaling pathway, p53 signaling pathway, and cell cycle regulation and TGF-beta signaling pathway are high-risk pathways that play a crucial role in the pathogenesis of FCD and refractory epilepsy. Our results suggest that the circulating miRNAs from exosomes may provide a potential biomarker for diagnostic, prognostic, and therapeutic adjuncts in patients with FCD and refractory epilepsy.

show abstract

“…Numerous studies have emphasized the core position of miRNAs in governing cancer development (13,14). miR-1183 was reported to be dysregulated in numerous human diseases (15)(16)(17) and Zhou et al (18) reported that miR-1183 functioned in the tumorigenesis of NSCLC. Nevertheless, the precise mechanism of miR-1183 in NScLc progression remains to be studied.…”

Section: Introductionmentioning

confidence: 99%

Circular RNA circ‑ACACA regulates proliferation, migration and glycolysis in non‑small‑cell lung�carcinoma via miR‑1183 and PI3K/PKB pathway

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

Non-small cell lung carcinoma (NScLc) accounts for 85% of all lung cancers and the five-year survival rate is ~1% in the late stage. circular RNAs (circRNAs) were reported to be involved in the progression of diverse human cancers. However, the role of circ-ACACA in NSCLC progression remains elusive. Quantitative polymerase chain reaction was conducted to detect the expression levels of circ-ACACA and microRNA (miR)-1183 in NScLc tissues and cells. A Cell Counting Kit-8 assay and transwell assay were employed to check proliferation and migration, respectively. Metabolic alternations in NSCLC cells were monitored by the Seahorse XFe96 analyzer. The protein levels of cellular myelocytomatosis, matrix metallopeptidase 9, glucose transporter 1, phosphatase and tensin homolog, phosphoinositide 3-kinases (PI3K), phosphorylated PI3K (p-PI3K), protein kinase B (PKB) and p-PKB in samples were measured by western blotting. The interaction between circ-AcAcA and miR-1183 was predicted by circular RNA Interactome, which was verified by dual-luciferase reporter assay, RNA immunoprecipitation assay and RNA pull-down assay. Xenograft tumor model was established to investigate the biological roles of circ-ACACA in vivo. The level of circ-ACACA was markedly upregulated in NSCLC tissues and cells, which was contrary to the expression of miR-1183. Knockdown of circ-AcAcA inhibited proliferation and migration of NScLc cells and also reduced the glycolysis rate. In addition, miR-1183 was a target of circ-ACACA and its downregulation reversed circ-ACACA silencing-mediated inhibitory impact on NSCLC progression. Further studies indicated that circ-AcAcA regulated the PI3K/PKB pathway through interacting with miR-1183 and downregulation of circ-AcAcA suppressed tumor growth. Knockdown of circ-ACACA impeded NSCLC progression by sponging miR-1183 and inactivating the PI3K/PKB signaling pathway.

show abstract

Expression of MicroRNAs miR-145, miR-181c, miR-199a and miR-1183 in the Blood and Hippocampus of Patients with Mesial Temporal Lobe Epilepsy

Cited by 25 publications

References 43 publications

MicroRNA Dysregulation in Epilepsy: From Pathogenetic Involvement to Diagnostic Biomarker and Therapeutic Agent Development

MicroRNA Dysregulation in Epilepsy: From Pathogenetic Involvement to Diagnostic Biomarker and Therapeutic Agent Development

Circulating MicroRNAs from Serum Exosomes May Serve as a Putative Biomarker in the Diagnosis and Treatment of Patients with Focal Cortical Dysplasia

Circular RNA circ‑ACACA regulates proliferation, migration and glycolysis in non‑small‑cell lung�carcinoma via miR‑1183 and PI3K/PKB pathway

Contact Info

Product

Resources

About